MabGalaxy

MabGalaxy, based in Beijing, China, focuses on developing innovative biotechnological solutions that enhance user experiences in various sectors, particularly through advanced software for data analytics and management. Founded in 2025 in Beijing, China, MabGalaxy operates in biotechnology, specializing in innovative solutions. The company has successfully completed one funding round, raising CNY 100 million in an Angel round on March 23, 2026, led by Lapam Capital. There are no noted pivots in business strategy or mention of subsidiaries.

The founder's history is not disclosed, nor is any previous entrepreneurial activity. MabGalaxy specializes in a range of innovative products aimed at enhancing user experiences across various sectors. Their core offerings include advanced software solutions designed for data analytics and management, catering to businesses in the technology and financial sectors. These products are engineered to streamline operations, improve decision-making processes, and enhance customer engagement through real-time data insights.

The company serves a diverse clientele, including small to medium-sized enterprises (SMEs) and large corporations, with a focus on markets in North America, Europe, and Asia. Their solutions have been increasingly adopted since their initial release, reflecting a growing demand for sophisticated analytical tools in today's data-driven landscape. MabGalaxy operates on a subscription-based revenue model, allowing clients to access their products and services through tiered pricing plans. These plans accommodate varying business needs, facilitating partnerships with both B2B clients and direct-to-consumer transactions.

Flagship services may include premium subscription tiers that offer enhanced features and dedicated support, fostering long-term relationships with customers. Revenue generation occurs through contract renewals and service upgrades, ensuring a steady income stream. This transactional framework demonstrates the company's commitment to delivering value while meeting the evolving requirements of its client base. In March 2026, MabGalaxy raised approximately CNY 100 million in Angel funding, led by new investor Lapam Capital, with participation from Nest.

Bio Labs, Yijing Investment, and YuanBio Venture. The company plans to utilize this funding to advance the development of core pipeline projects, upgrade its technology platform, expand its team, and accelerate the preclinical research and subsequent development of multiple innovative antibody projects. MabGalaxy aims to launch new products and expand into additional markets, though specific release dates and targeted regions for expansion have not been disclosed.